HZNP Horizon Therapeutics Public Limited Company

26.75
+0.34  (+1%)
Previous Close 26.41
Open 26.52
Price To Book 3.28
Market Cap 4,987,479,185
Shares 186,447,820
Volume 210,953
Short Ratio
Av. Daily Volume 1,392,791

NewsSee all news

  1. Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

    -- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has

  2. Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

    - Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN – August 28, 2019 – Horizon Therapeutics plc (NASDAQ:HZNP) today named Andy Pasternak executive

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 2 trial initiation announced September 27, 2018.
Krystexxa with Methotrexate
Gout
Randomized trial initiation announced June 20, 2019.
Krystexxa with Methotrexate - MIRROR RCT
Gout
PDUFA date under priority review March 8, 2020.
Teprotumumab
Thyroid Eye Disease (TED)

Latest News

  1. Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

    -- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has

  2. Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

    - Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN – August 28, 2019 – Horizon Therapeutics plc (NASDAQ:HZNP) today named Andy Pasternak executive